| 前收盘价格 | 0.091 |
| 收盘价格 | 0.091 |
| 成交量 | 32,970,866 |
| 平均成交量 (3个月) | 142,879,214 |
| 市值 | 33,773,016 |
| 股市价格/股市净资产 (P/B) | 0.100 |
| 52周波幅 | |
| 利润日期 | 13 Aug 2025 - 18 Aug 2025 |
| 稀释每股收益 (EPS TTM) | -5.05 |
| 总债务/股东权益 (D/E MRQ) | 4.15% |
| 流动比率 (MRQ) | 1.25 |
| 营业现金流 (OCF TTM) | -16.34 M |
| 杠杆自由现金流 (LFCF TTM) | -12.46 M |
| 资产报酬率 (ROA TTM) | -59.80% |
| 股东权益报酬率 (ROE TTM) | -204.60% |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 看跌 | 看跌 |
| Biotechnology (全球的) | 看跌 | 看跌 | |
| 股票 | NuCana plc | 混合的 | 看跌 |
AIStockmoo 评分
-0.9
| 分析师共识 | -2.0 |
| 内部交易活动 | NA |
| 价格波动 | -2.0 |
| 技术平均移动指标 | 1.0 |
| 技术振荡指标 | -0.5 |
| 平均 | -0.88 |
|
NuCana PLC is a biopharmaceutical company focused on improving treatment outcomes for cancer patients by ProTide technology. Utilizing proprietary ProTide technology, the firm is developing new medicines designed to overcome key cancer resistance mechanisms and generate much higher concentrations of anti-cancer metabolites in cancer cells. The company's ProTide pipeline products are NUC-3373, NUC-7738, Acelarin. Geographically operates through the region of the United States. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 0.15% |
| 机构持股比例 | 5.61% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Glass Jacobson Investment Advisors Llc | 31 Mar 2025 | 15,000 |
该时间范围内无数据。
该时间范围内无数据。
| 日期 | 类型 | 细节 |
|---|---|---|
| 02 Jun 2025 | 公告 | NuCana Reports First Quarter 2025 Financial Results and Provides Business Update |
| 02 Jun 2025 | 公告 | NuCana Reports First Quarter 2025 Financial Results and Provides Business Update |
| 06 May 2025 | 公告 | NuCana Prices $7 Million Registered Direct Offering |
| 06 May 2025 | 公告 | NuCana Prices $7 Million Registered Direct Offering |
支撑、阻力和趋势线水平是由人工智能（AI）模型生成的，请谨慎解读。
投资组合